September 10, 2025CellsOpen Access

Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

In vitro analysis demonstrates efficacy of tyrosine kinase inhibitors for uncommon EGFR mutations in NSCLC, suggesting potential treatment avenues.

Afatinib showed broad activity against all tested uncommon EGFR mutations, including Del18 and L861Q.
Novel third-generation TKIs were effective against L861Q and specific exon 18 mutations, but not the S768I mutation.
Secondary mutations such as T790M and T725M can arise from afatinib or osimertinib treatment, respectively.
Lazertinib emerged as a viable option for overcoming resistance in afatinib or osimertinib-treated models.

Oiki et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

In vitro analysis demonstrates efficacy of tyrosine kinase inhibitors for uncommon EGFR mutations in NSCLC, suggesting potential treatment avenues.